证券代码：839729 证券简称：永顺生物 公告编号：2022-048 广东永顺生物制药股份有限公司 关于接待机构投资者调研情况的公告 | --- | |------------------------------------------------------------------------| | | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 | | 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 | | 带法律责任。 | 广东永顺生物制药股份有限公司（以下简称"公司"）于 2022 年 5 月 11 日接待了 8 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2022 年 5 月 11 日 调研地点：广东永顺生物制药股份有限公司二楼会议室 调研形式：现场调研 调研机构：长城证券股份有限公司、广东丰盛长天投资有限公司、广州永沣 投资控股有限公司、广州和易控股有限公司、吉富创业投资股份有限公司、国盛 证券有限责任公司、佛山泓文投资咨询有限公司、海通期货股份有限公司 上市公司接待人员：副总经理、董事会秘书吴子舟，总经理助理杨傲冰 二、 ...

证券代码：839729 证券简称：永顺生物 公告编号：2022-065 广东永顺生物制药股份有限公司 关于接待机构投资者调研情况的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 广东永顺生物制药股份有限公司（以下简称"公司"）于 2022 年 9 月 20 日接待了 8 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2022 年 9 月 20 日 调研地点：广东永顺生物制药股份有限公司二楼会议室 调研形式：现场调研 调研机构：湘财证券股份有限公司、第一创业证券股份有限公司、中金资本 管理广东有限公司、广发银行股份有限公司、广东弘图广电投资有限公司、中信 银行股份有限公司、交通银行股份有限公司、广州华宸管理咨询有限公司 上市公司接待人员：董事、总经理林德锐先生，副总经理、董事会秘书吴子 舟先生，财务负责人李秋红女士 二、 调研的主要问题及公司回复概要 问题 1：国产宠物疫苗，药品需求大，未来前景可观，贵公司未来的业务是 否会考虑加大宠物相关疫苗的投资研发？ 回复：我国宠物行业规模基 ...

证券代码：839729 证券简称：永顺生物 公告编号：2022-068 广东永顺生物制药股份有限公司 关于接待机构投资者调研情况的公告 | --- | --- | |------------------------------------------------------------------------|-------| | | | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 | | | 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 | | | 带法律责任。 | | 广东永顺生物制药股份有限公司（以下简称"公司"）于 2022 年 9 月 27 日接待了 6 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2022 年 9 月 27 日 调研地点：广东永顺生物制药股份有限公司二楼会议室 调研形式：现场调研 调研机构：海通证券股份有限公司、海通期货股份有限公司、广东金羊基金 管理有限公司、广州市罗爵资产管理有限公司、广州中投立赢私募证券投资基金 管理有限公司、招商银行股份有限公司 上市公司接待人员：副总经理、董事会秘书吴子舟先生，财务 ...

广东永顺生物制药股份有限公司 公告编号：2022-071 永顺生物 证券代码 : 839729 广东永顺生物制药股份有限公司 2022 年第三季度报告 1 / 28 | 第一节 | 重要提示 | 4 | | --- | --- | --- | | 第二节 | 公司基本情况 | 5 | | 第三节 | 重大事件 | 13 | | 第四节 | 财务会计报告 | 17 | 广东永顺生物制药股份有限公司 公告编号：2022-071 | 释义项目 | | | | 释义 | | | | --- | --- | --- | --- | --- | --- | --- | | 公司、本公司、永顺生物 | 指 | 广东永顺生物制药股份有限公司 | | | | | | 现代农业集团 | 指 | 广东省现代农业集团有限公司 | | | | | | 农科资产经营 | 指 | 广东省农科资产经营有限公司 | | | | | | 动物卫生研究所 | 指 | 广东省农业科学院动物卫生研究所 | | | | | | 股东大会 | 指 | 广东永顺生物制药股份有限公司股东大会 | | | | | | 董事会 | 指 | 广东永顺生物制药股份有 ...

Regulatory Approvals and Certifications - In February 2022, the company received production approval for two avian influenza vaccines, with approval numbers 190592368 and 190592369[3]. - The company has received a high-tech enterprise certificate valid for three years, allowing a reduced corporate income tax rate of 15% for the years 2020 to 2022[11]. - The company has obtained two new veterinary drug certificates for aquatic vaccines, but market recognition is lower than expected, leading to no revenue from these products yet[11]. - The company holds 22 authorized patents, including 13 invention patents, and has 18 vaccine products under research and development[10]. - The company has developed a new cell culture production technology for animal vaccines, which has received national patent authorization[31]. Financial Performance - The company's operating revenue for the current period is CNY 155,508,444.83, a decrease of 17.35% compared to CNY 188,160,457.30 in the same period last year[25]. - The net profit attributable to shareholders of the listed company is CNY 35,315,527.79, down 39.00% from CNY 57,890,814.02 in the previous year[25]. - The gross profit margin has decreased to 64.67% from 71.27% year-on-year[25]. - The basic earnings per share have dropped to 0.13 from 0.21, reflecting a decline of 38.10%[25]. - Non-recurring gains and losses impacted the net profit by RMB 6,999,400, representing 19.82% of the net profit for the period[10]. Revenue Sources and Distribution - The revenue from the distribution model accounted for 28.33% of the total operating income during the reporting period[10]. - Vaccine sales revenue was 150.60 million yuan, down 20.04 million yuan, or 11.74% year-on-year, mainly due to delays in government procurement caused by changes in avian influenza strains[41]. - Revenue from technology transfer was CNY 4,906,809.03, a significant drop of 71.90% year-on-year[60]. - The revenue from inactivated poultry vaccines fell by 24.72% to CNY 49,005,225.05, with a gross margin of 31.06%[57]. Operational Challenges and Risks - The company faces risks related to fluctuations in the livestock and poultry farming industry, which could affect vaccine demand and overall performance[9]. - The company faces risks related to the inability to recover accounts receivable on time, which could adversely affect operational performance[11]. - Environmental protection measures have increased operational costs, and failure to comply with national standards could harm the company's reputation and operations[11]. - The company is focusing on enhancing product quality and technical improvements, including the acquisition of an energy online monitoring system to reduce costs and improve efficiency[42]. Shareholder and Governance Information - The company has a total of 273,350,000 shares, with 80,244,567 shares (29.36%) being unrestricted and 193,105,433 shares (70.64%) being restricted[111]. - Major shareholders have signed commitments to avoid competition and reduce related party transactions, with these commitments being fulfilled during the reporting period[101][102]. - The company has no controlling shareholder or actual controller, ensuring independence in governance[133]. - The management team has committed to improving corporate governance structures, which is currently in progress[93]. Cash Flow and Investment - Operating cash flow decreased by 38.80% to ¥20,595,869.57, reflecting reduced operational efficiency[27]. - The company reported a net cash flow from operating activities of CNY 20,595,869.57, a decline of 38.80% from the previous year[63]. - The company has utilized CNY 8,785,773.95 of the raised funds for working capital, which is 99.99% of the planned amount[127]. - The total amount of raised funds that have been changed in purpose is CNY 0, indicating compliance with regulatory requirements[126]. Research and Development - The company invested 12.13 million yuan in R&D, accounting for 7.80% of operating revenue, and obtained 1 utility model patent and 2 clinical trial approvals for veterinary biological products[42]. - The company is focusing on enhancing its R&D management and collaboration with research institutions to reduce the uncertainty in new product development[78]. Market Position and Strategy - The company is designated as a key producer of high pathogenic avian influenza vaccines, with sales primarily through government procurement[9]. - The company plans to enhance its product line and sales channels to mitigate risks associated with fluctuations in the livestock breeding industry[71]. - The company aims to improve its market share by increasing development efforts with distributors and large-scale breeding customers[73]. Compliance and Legal Matters - There are no significant lawsuits or arbitration matters reported during the period, with a total claim amount of 4.98 million yuan, representing 0.75% of net assets[87]. - The company has no reported instances of shareholders or related parties occupying or transferring company funds or assets[88]. - The company has made provisions for bad debts according to established accounting policies, but risks remain if major clients face financial difficulties[82].

广东永顺生物制药股份有限公司 公告编号：2022-046 永顺生物 证券代码 : 839729 广东永顺生物制药股份有限公司 广东永顺生物制药股份有限公司 公告编号：2022-046 第一节 重要提示 公司董事、监事、高级管理人员保证本报告所载资料不存在虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担个别及连带责任。 公司负责人谭德明、主管会计工作负责人李秋红及会计机构负责人（会计主管人员）冯旦家保证季 度报告中财务报告的真实、准确、完整。 2022 年第一季度报告 1 | 第一节 | 重要提示 | 4 | | --- | --- | --- | | 第二节 | 公司基本情况 | 5 | | 第三节 | 重大事件 11 | | | 第四节 | 财务会计报告 | 14 | 广东永顺生物制药股份有限公司 公告编号：2022-046 | 释义项目 | | 释义 | | | | --- | --- | --- | --- | --- | | 公司、本公司、永顺生物 | 指 | 广东永顺生物制药股份有限公司 | | | | 现代农业集团 | 指 | 广东省现代农业集团有限公司 | | | | ...

Company Achievements and Certifications - In 2021, the company successfully obtained the "High-tech Enterprise Certificate" from the Guangdong Provincial Department of Science and Technology, indicating its continued recognition as a high-tech enterprise[3]. - The company’s two flagship products, the pig fever live vaccine and the pig circovirus type 2 inactivated vaccine, were selected as 2020 Guangdong Province's high-quality high-tech products[3]. - The company was awarded the "Top 20 Agricultural Science and Technology Innovation Enterprises" in Guangdong Province during the 13th Five-Year Plan period[4]. - The company achieved compliance with the new veterinary drug GMP requirements and was granted the veterinary drug GMP certificate in June 2021[4]. - The company has obtained 21 authorized patents, including 13 invention patents, and is advancing multiple veterinary vaccine projects[12]. Financial Performance - The company's operating revenue for 2021 was CNY 363,525,642.57, representing a 9.30% increase compared to CNY 332,589,593.88 in 2020[28]. - The net profit attributable to shareholders for 2021 was CNY 91,342,217.51, which is a 13.86% increase from CNY 80,220,685.80 in 2020[28]. - The gross profit margin improved to 67.43% in 2021 from 65.78% in 2020[28]. - The company's cash flow from operating activities for 2021 was CNY 100,703,991.33, up 9.94% from CNY 91,596,129.70 in 2020[32]. - The company's total share capital at the end of 2021 was 273,350,000 shares, a 250.00% increase from 78,100,000 shares at the end of 2020[35]. Risks and Challenges - The company faces risks related to fluctuations in the livestock and poultry breeding industry, which can impact the demand for veterinary vaccines[11]. - The company’s main product, the highly pathogenic avian influenza inactivated vaccine, is subject to procurement policy changes by the government, which poses a risk to its operations[11]. - Risks include potential changes in government procurement policies and the need for timely product updates to maintain profitability[12]. - The company faces risks related to the sustainability of cooperative research and technology introduction partnerships[13]. - The company has a risk of product quality issues, which could impact its reputation and lead to potential penalties[127]. Research and Development - The company has multiple ongoing R&D projects, including vaccines that are in various stages of approval and registration[55]. - The company has developed 29 types of vaccines, including single, multi, and multi-combination vaccines, with a strong market presence in the pig vaccine sector[46]. - The company is currently developing multiple projects, including a vaccine for Mycoplasma pneumonia in pigs, which is in the new veterinary drug certificate approval stage[102]. - The company is focusing on improving its R&D capabilities to expedite the market introduction of new products[120]. - The application of genetic engineering technology in poultry vaccines has matured, leading to technological upgrades in the poultry vaccine sector[117]. Market and Sales Strategy - The company employs a "sales-driven production" model, adjusting production plans based on sales forecasts and market feedback[46]. - The sales strategy includes both government tender procurement and market-based sales, with differentiated approaches for small and large-scale customers[50]. - Vaccine sales revenue reached 345.07 million yuan, up 17.15 million yuan, or 5.23%, due to increased sales to major clients and overseas markets[54]. - The company plans to enhance its market layout and expand both domestic and international markets, particularly in poultry vaccines, to increase market share[122]. - The company is actively expanding its supplier base to ensure quality and cost-effectiveness, resulting in a decrease in the procurement proportion from the top five suppliers compared to the previous year[84]. Corporate Governance and Compliance - The company has committed to further improving corporate governance following its listing in November 2016[150]. - The company has made a commitment to ensure that its internal control systems are continuously improved, with no significant failures reported during the period[159]. - The company has engaged in related transactions with the Guangdong Academy of Agricultural Sciences, including a contract amount of CNY 5 million for R&D technical services, with CNY 2.5 million actually incurred[148]. - The company has committed to avoiding related party transactions and conflicts of interest, which are currently being fulfilled[149]. - The company has maintained compliance with commitments related to related party transactions, share lock-up, and reduction intentions during the reporting period[162]. Environmental Compliance - The company has a wastewater treatment capacity of 200 cubic meters per day, ensuring compliance with environmental protection measures[114]. - The company’s main pollutants include wastewater, waste gas, solid waste, and noise, with specific measures in place for their treatment and reduction[114]. - The company is actively working with third-party waste disposal agencies to ensure compliance with environmental regulations[115]. - The company is committed to complying with environmental regulations to avoid potential pollution incidents and associated costs[138]. - Environmental protection measures are in place, but failure to comply with increasing standards could negatively impact operations and reputation[13].